Cannabis preparations are the most widely consumed illicit drugs, and their use typically begins in adolescence. The prevalence of cannabis abuse is higher in patients with attention deficit/hyperactivity disorder (ADHD) than in the general population, yet, knowledge about the motivational properties of cannabinoids in animal models of ADHD are lacking.
To compare the motivational effects of the synthetic cannabinoid agonist WIN55,212-2 (WIN) in adolescent and adult spontaneously hypertensive rats (SHR), a validated animal model of ADHD, and Wistar rats, representing a “normal” genetically heterogeneous population. We also asked whether the effects of WIN depended (1) on the activation of the cerebral subtype of cannabinoid receptors, namely, the CB1 cannabinoid receptor and (2) on putative changes by WIN in blood pressure.
WIN was tested under an unbiased conditioned place preference (CPP) paradigm. Blood pressure after WIN administration was also monitored in additional groups of rats.
In the Wistar rats, WIN produced place aversion only in the adult but not adolescent rats. In contrast, WIN produced CPP in both adolescent and adult SHR rats. The behavioral effects of WIN were CB1-mediated and not related to blood pressure.
The contrasting effects of WIN in Wistar and SHR, and the higher resistance of adolescent rats to the aversive and rewarding effects of WIN in these two strains suggests that both adolescence and the ADHD-like profile exhibited by the SHR strain constitute factors that influence the motivational properties of cannabinoids.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Adriani W, Laviola G. Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model. Behav Pharmacol. 2004;15:341–352.
Adriani W, Seta DD, Dessi-Fulgheri F, Farabollini F, Laviola G. Altered profiles of spontaneous novelty seeking, impulsive behavior, and response to d-amphetamine in rats perinatally exposed to bisphenol A. Environ Health Perspect. 2003;111:395–401.
Andersen SL, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon WA Jr. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci. 2002;5:13–14.
Augustyniak PN, Kourrich S, Rezazadeh SM, Stewart J, Arvanitogiannis A. Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav Brain Res. 2006;167:379–382.
Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004;110:1996–2002.
Biederman J, Faraone SV, Spencer T, Wilens T, Mick E, Lapey KA. Gender differences in a sample of adults with attention deficit hyperactivity disorder. Psychiatry Res. 1994;53:13–29.
Biederman J, Monuteaux MC, Mick E, Spencer T, Wilens TE, Silva JM, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36:167–179.
Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol. 2004;506:63–69.
Carney JM, Uwaydah IM, Balster RL. Evaluation of a suspension system for intravenous self-administration studies of water-insoluble compounds in the rhesus monkey. Pharmacol Biochem Behav. 1977;7:357–364.
Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry. 2003;160:1041–1052.
Chiu P, Rajakumar G, Chiu S, Kwan CY, Mishra RK. Enhanced [3H]spiroperidol binding in striatum of spontaneously hypertensive rat (SHR). Eur J Pharmacol. 1982;82:243–244.
Crews F, He J, Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol Biochem Behav. 2007;86:189–199.
Crowley TJ, Macdonald MJ, Whitmore EA, Mikulich SK. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend. 1998;50:27–37.
Da Silva GE, Vendruscolo LF, Takahashi RN. Effects of ethanol on locomotor and anxiety-like behaviors and the acquisition of ethanol intake in Lewis and spontaneously hypertensive rats. Life Sci. 2005;77:693–706.
Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Animal models of attention-deficit hyperactivity disorder. Brain Res Brain Res Rev. 2003;42:1–21.
Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P, et al. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology. 2007;52:646–654.
Fattore L, Cossu G, Martellotta CM, Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55, 212–2 in rats. Psychopharmacology (Berl). 2001;156:410–416.
Gardner EL, Paredes W, Smith D, Donner A, Milling C, Cohen D, et al. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology (Berl). 1988;96:142–144.
Himelstein J, Newcorn JH, Halperin JM. The neurobiology of attention-deficit hyperactivity disorder. Front Biosci. 2000;5:461–478.
Hoffmann O, Plesan A, Wiesenfeld-Hallin Z. Genetic differences in morphine sensitivity, tolerance and withdrawal in rats. Brain Res. 1998;806:232–237.
Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta(9)-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 2003;169:135–140.
Köfalvi A, Fritzsche M (2008) The Endocannabinoid System is a Major Player in Schizophrenia. In: Köfalvi, A. (Ed.), Cannabinoids and the Brain. Springer US, pp. 485-528. doi:10.1007/978-0-387-74349-3_22
Lake KD, Compton DR, Varga K, Martin BR, Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther. 1997;281:1030–1037.
Leite JR, Carlini EA. Failure to obtain “cannabis-directed behavior” and abstinence syndrome in rats chronically treated with cannabis sativa extracts. Psychopharmacologia. 1974;36:133–145.
Lepore M, Vorel SR, Lowinson J, Gardner EL. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci. 1995;56:2073–2080.
Maharajan P, Maharajan V, Ravagnan G, Paino G. The weaver mutant mouse: a model to study the ontogeny of dopamine transmission systems and their role in drug addiction. Prog Neurobiol. 2001;64:269–276.
Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006;29:225–232.
Mansbach RS, Nicholson KL, Martin BR, Balster RL. Failure of Delta(9)-tetrahydrocannabinol and CP 55, 940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav Pharmacol. 1994;5:219–225.
Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55, 212–2 in drug-naive mice. Neuroscience. 1998;85:327–330.
McGregor IS, Issakidis CN, Prior G. Aversive effects of the synthetic cannabinoid CP 55, 940 in rats. Pharmacol Biochem Behav. 1996;53:657–664.
McKeon TW, Hendley ED. Brain monoamines and metabolites in hypertensive and hyperactive rat strains. Clin Exp Hypertens. 1988;10:971–994.
Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J. 1963;27:282–293.
Pamplona FA, Prediger RD, Pandolfo P, Takahashi RN. The cannabinoid receptor agonist WIN 55, 212–2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology (Berl). 2006;188:641–649.
Pamplona FA, Vendruscolo LF, Takahashi RN. Increased sensitivity to cocaine-induced analgesia in Spontaneously Hypertensive Rats (SHR). Behav Brain Funct. 2007;3:9.
Pandolfo P, Pamplona FA, Prediger RD, Takahashi RN. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55, 212–2. Eur J Pharmacol. 2007;563:141–148.
Papa M, Diewald L, Carey MP, Esposito FJ, Gironi Carnevale UA, Sadile AG. A rostro-caudal dissociation in the dorsal and ventral striatum of the juvenile SHR suggests an anterior hypo- and a posterior hyperfunctioning mesocorticolimbic system. Behav Brain Res. 2002;130:171–179.
Parker LA, Gillies T. THC-induced place and taste aversions in Lewis and Sprague–Dawley rats. Behav Neurosci. 1995;109:71–78.
Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, et al. Adolescent rats find repeated delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology. 2008;33:1113–1126.
Ramos A, Kangerski AL, Basso PF, Da Silva Santos JE, Assreuy J, Vendruscolo LF, et al. Evaluation of Lewis and SHR rat strains as a genetic model for the study of anxiety and pain. Behav Brain Res. 2002;129:113–123.
Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA. 2002;99:8384–8388.
Russell V, de Villiers A, Sagvolden T, Lamm M, Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder—the spontaneously hypertensive rat. Brain Res. 1995;676:343–351.
Russell VA, de Villiers AS, Sagvolden T, Lamm MC, Taljaard JJ. Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit/hyperactivity disorder–the spontaneously hypertensive rat. Brain Res Bull. 2000;53:187–192.
Russell VA, Sagvolden T, Johansen EB. Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct. 2005;1:9.
Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev. 2000;24:31–39.
Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1239–1247.
Sanudo-Pena MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett. 1997;223:125–128.
Spear LP. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev. 2000;24:417–463.
Spear LP, Brake SC. Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol. 1983;16:83–109.
Takahashi RN, Singer G. Self-administration of delta 9-tetrahydrocannabinol by rats. Pharmacol Biochem Behav. 1979;11:737–740.
Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci. 2000;3:1073–1074.
Taylor E. Clinical foundations of hyperactivity research. Behav Brain Res. 1998;94:11–24.
Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol. 2007;12:227–462.
Valjent E, Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology (Berl). 2000;147:436–438.
van Ree JM, Slangen JL, de Wied D. Intravenous self-administration of drugs in rats. J Pharmacol Exp Ther. 1978;204:547–557.
Vendruscolo LF, Izidio GS, Takahashi RN, Ramos A. Chronic methylphenidate treatment during adolescence increases anxiety-related behaviors and ethanol drinking in adult spontaneously hypertensive rats. Behav Pharmacol. 2008;19:21–27.
Vendruscolo LF, Izídio GS, Takahashi RN. Drug reinforcement in a rat model of attention deficit/hyperactivity disorder – the spontaneously hypertensive rat (SHR). Current Drug Abuse Reviews. 2009, in press
Viggiano D, Vallone D, Ruocco LA, Sadile AG. Behavioural, pharmacological, morpho-functional molecular studies reveal a hyperfunctioning mesocortical dopamine system in an animal model of attention deficit and hyperactivity disorder. Neurosci Biobehav Rev. 2003;27:683–689.
Vlachou S, Nomikos GG, Panagis G. CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology (Berl). 2005;179:498–508.
Vlachou S, Nomikos GG, Stephens DN, Panagis G. Lack of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents. Behav Pharmacol. 2007;18:311–319.
Watanabe Y, Fujita M, Ito Y, Okada T, Kusuoka H, Nishimura T. Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med. 1997;38:470–474.
Wheal AJ, Bennett T, Randall MD, Gardiner SM. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol. 2007;152:717–724.
Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA. Two brain sites for cannabinoid reward. J Neurosci. 2006;26:4901–4907.
The authors are grateful to Dr. Jamil Assreuy for his expert assistance in blood pressure measurements and to Dr. Attila Köfalvi and Dr. Kelly J. Clemens for helpful comments. P.P. and R.S. are supported by scholarships from CNPq, Brazil. L.F.V. had a post-doctoral fellowship from FONDATION FYSSEN, France. R.N.T. is the holder of a CNPq fellowship.
About this article
Cite this article
Pandolfo, P., Vendruscolo, L.F., Sordi, R. et al. Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat–an animal model of attention deficit hyperactivity disorder. Psychopharmacology 205, 319–326 (2009). https://doi.org/10.1007/s00213-009-1542-3
- Attention deficit hyperactivity disorder (ADHD)
- Drug addiction
- Cannabinoid system
- Conditioned place preference
- Inbred strain
- Spontaneously hypertensive rat (SHR)